Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges

Breast cancer is one of the most common causes of cancer-related morbidity and mortality in women worldwide. Early diagnosis and an appropriate therapeutic approach for all cancers are climacterics for a favorable prognosis. Targeting the immune system in breast cancer is already a clinical reality...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 14; no. 12; pp. 957 - 983
Main Authors Ahmad, Mohammad Zaki, Alasiri, Ali S, Alasmary, Mohammed Yahia, Abdullah, MM, Ahmad, Javed, Abdel Wahab, Basel A, M Alqahtani, Saif Aboud, Pathak, Kalyani, Mustafa, Gulam, Khan, Mohammad Ahmad, Saikia, Riya, Gogoi, Urvashee
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.08.2022
Subjects
breast cancer
cancer immunotherapy
cancer nanovaccines
nanomedicine
nanoparticles
vaccines
breast cancer
nanomedicine
nanoparticles
cancer nanovaccines
vaccines
cancer immunotherapy
Online AccessGet full text
ISSN1750-743X
1750-7448
DOI10.2217/imt-2021-0348

Cover

Abstract Breast cancer is one of the most common causes of cancer-related morbidity and mortality in women worldwide. Early diagnosis and an appropriate therapeutic approach for all cancers are climacterics for a favorable prognosis. Targeting the immune system in breast cancer is already a clinical reality with notable successes, specifically with checkpoint blockade antibodies and chimeric antigen receptor T-cell therapy. However, there have been inevitable setbacks in the clinical application of cancer immunotherapy, including inadequate immune responses due to insufficient delivery of immunostimulants to immune cells and uncontrolled immune system modulation. Rapid advancements and new evidence have suggested that nanomedicine-based immunotherapy may be a viable option for treating breast cancer. Cancer that begins in the breast is referred to as breast cancer. It may originate in either one or both breasts. It is one of the main causes of cancer-related death among women worldwide. Cancer immunotherapy is a game-changing treatment that improves the ability of the host defense system to spot and eliminate cancer cells with pinpoint accuracy. Cancer immunotherapy, also referred to as immuno-oncology, is a type of treatment option for breast cancer that uses the body’s natural defense system to prevent, regulate and eliminate breast cancer. Immunotherapy is used to enhance or alter the functioning of the immune system so that it can locate and destroy cancer cells. Knowing how immunotherapy works and what to anticipate can often offer peace of mind to the patient who can then make informed decisions about care, especially if immunotherapy is part of the treatment plan for a particular patient. Breast cancer is the most common cancer in women. Rapid advancements and new evidence have suggested that #nanomedicine-based immunotherapy may be a viable option for treating #breastcancer
AbstractList Breast cancer is one of the most common causes of cancer-related morbidity and mortality in women worldwide. Early diagnosis and an appropriate therapeutic approach for all cancers are climacterics for a favorable prognosis. Targeting the immune system in breast cancer is already a clinical reality with notable successes, specifically with checkpoint blockade antibodies and chimeric antigen receptor T-cell therapy. However, there have been inevitable setbacks in the clinical application of cancer immunotherapy, including inadequate immune responses due to insufficient delivery of immunostimulants to immune cells and uncontrolled immune system modulation. Rapid advancements and new evidence have suggested that nanomedicine-based immunotherapy may be a viable option for treating breast cancer. Cancer that begins in the breast is referred to as breast cancer. It may originate in either one or both breasts. It is one of the main causes of cancer-related death among women worldwide. Cancer immunotherapy is a game-changing treatment that improves the ability of the host defense system to spot and eliminate cancer cells with pinpoint accuracy. Cancer immunotherapy, also referred to as immuno-oncology, is a type of treatment option for breast cancer that uses the body’s natural defense system to prevent, regulate and eliminate breast cancer. Immunotherapy is used to enhance or alter the functioning of the immune system so that it can locate and destroy cancer cells. Knowing how immunotherapy works and what to anticipate can often offer peace of mind to the patient who can then make informed decisions about care, especially if immunotherapy is part of the treatment plan for a particular patient. Breast cancer is the most common cancer in women. Rapid advancements and new evidence have suggested that #nanomedicine-based immunotherapy may be a viable option for treating #breastcancer
Breast cancer is one of the most common causes of cancer-related morbidity and mortality in women worldwide. Early diagnosis and an appropriate therapeutic approach for all cancers are climacterics for a favorable prognosis. Targeting the immune system in breast cancer is already a clinical reality with notable successes, specifically with checkpoint blockade antibodies and chimeric antigen receptor T-cell therapy. However, there have been inevitable setbacks in the clinical application of cancer immunotherapy, including inadequate immune responses due to insufficient delivery of immunostimulants to immune cells and uncontrolled immune system modulation. Rapid advancements and new evidence have suggested that nanomedicine-based immunotherapy may be a viable option for treating breast cancer.
Author Alasiri, Ali S
Khan, Mohammad Ahmad
Abdel Wahab, Basel A
M Alqahtani, Saif Aboud
Saikia, Riya
Gogoi, Urvashee
Ahmad, Mohammad Zaki
Ahmad, Javed
Pathak, Kalyani
Alasmary, Mohammed Yahia
Abdullah, MM
Mustafa, Gulam
AuthorAffiliation 6Internal Medicine Department, College of Medicine, King Khalid University, Abha, 61421, Kingdom of Saudi Arabia
9Department of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India
4Department of Pharmacology, College of Pharmacy, Najran University, Najran, 11001, Kingdom of Saudi Arabia
1Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Najran, 11001, Kingdom of Saudi Arabia
3Advanced Materials & Nano-Research Centre, Department of Physics, Faculty of Science & Arts, Najran University, Najran, 11001, Kingdom Saudi Arabia
7Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India
8College of Pharmacy, Shaqra University, Ad-Dawadmi Riyadh, Kingdom of Saudi Arabia
2Medical Department, College of Medicine, Najran University, Najran, 11001, Kingdom of Saudi Arabia
5Department of Pharmacology, College of Medicine, Assiut University, Assiut, 71515, Egypt
AuthorAffiliation_xml – name: 6Internal Medicine Department, College of Medicine, King Khalid University, Abha, 61421, Kingdom of Saudi Arabia
– name: 8College of Pharmacy, Shaqra University, Ad-Dawadmi Riyadh, Kingdom of Saudi Arabia
– name: 9Department of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India
– name: 3Advanced Materials & Nano-Research Centre, Department of Physics, Faculty of Science & Arts, Najran University, Najran, 11001, Kingdom Saudi Arabia
– name: 4Department of Pharmacology, College of Pharmacy, Najran University, Najran, 11001, Kingdom of Saudi Arabia
– name: 1Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Najran, 11001, Kingdom of Saudi Arabia
– name: 2Medical Department, College of Medicine, Najran University, Najran, 11001, Kingdom of Saudi Arabia
– name: 5Department of Pharmacology, College of Medicine, Assiut University, Assiut, 71515, Egypt
– name: 7Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India
Author_xml – sequence: 1
  givenname: Mohammad Zaki
  orcidid: 0000-0003-2979-8776
  surname: Ahmad
  fullname: Ahmad, Mohammad Zaki
  organization: Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Najran, 11001, Kingdom of Saudi Arabia
– sequence: 2
  givenname: Ali S
  surname: Alasiri
  fullname: Alasiri, Ali S
  organization: Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Najran, 11001, Kingdom of Saudi Arabia
– sequence: 3
  givenname: Mohammed Yahia
  surname: Alasmary
  fullname: Alasmary, Mohammed Yahia
  organization: Medical Department, College of Medicine, Najran University, Najran, 11001, Kingdom of Saudi Arabia
– sequence: 4
  givenname: MM
  orcidid: 0000-0002-0604-5360
  surname: Abdullah
  fullname: Abdullah, MM
  organization: Advanced Materials & Nano-Research Centre, Department of Physics, Faculty of Science & Arts, Najran University, Najran, 11001, Kingdom Saudi Arabia
– sequence: 5
  givenname: Javed
  orcidid: 0000-0002-7025-751X
  surname: Ahmad
  fullname: Ahmad, Javed
  organization: Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Najran, 11001, Kingdom of Saudi Arabia
– sequence: 6
  givenname: Basel A
  orcidid: 0000-0002-5545-6422
  surname: Abdel Wahab
  fullname: Abdel Wahab, Basel A
  organization: Department of Pharmacology, College of Pharmacy, Najran University, Najran, 11001, Kingdom of Saudi Arabia, Department of Pharmacology, College of Medicine, Assiut University, Assiut, 71515, Egypt
– sequence: 7
  givenname: Saif Aboud
  orcidid: 0000-0002-9812-6562
  surname: M Alqahtani
  fullname: M Alqahtani, Saif Aboud
  organization: Internal Medicine Department, College of Medicine, King Khalid University, Abha, 61421, Kingdom of Saudi Arabia
– sequence: 8
  givenname: Kalyani
  orcidid: 0000-0002-1421-8962
  surname: Pathak
  fullname: Pathak, Kalyani
  organization: Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India
– sequence: 9
  givenname: Gulam
  surname: Mustafa
  fullname: Mustafa, Gulam
  organization: College of Pharmacy, Shaqra University, Ad-Dawadmi Riyadh, Kingdom of Saudi Arabia
– sequence: 10
  givenname: Mohammad Ahmad
  surname: Khan
  fullname: Khan, Mohammad Ahmad
  organization: Department of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India
– sequence: 11
  givenname: Riya
  surname: Saikia
  fullname: Saikia, Riya
  organization: Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India
– sequence: 12
  givenname: Urvashee
  surname: Gogoi
  fullname: Gogoi, Urvashee
  organization: Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35852105$$D View this record in MEDLINE/PubMed
BookMark eNp1kE1LxDAQhoMo7ocevUr-QDVNmrbrTZb1Axa8KHgLaTrdjbRJSVJh_70pdT0Ie5pMeN5h5lmgc2MNIHSTkjtK0-JedyGhhKYJYVl5huZpwUlSZFl5_vdmnzO08P6LkDwr8uwSzRgvOU0JnyOx6cDttNlhWX9Lo8BjbbCRxnZQa6UN4MY6XDmQPmA1Eg7rrhuMDXtwsj88YNv31oXB6KBjXJoaq71sWzA78FfoopGth-vfukQfT5v39UuyfXt-XT9uE0V5GS9oCK0p5yzuxascKKmI4kDyUkrKVqmilDWcygoYLSPcVCSLdLXinKhV_F2i22luP1Rxc9E73Ul3EMdLI8AmQDnrvYNGKB1k0NYEJ3UrUiJGnyL6FKNPMfqMqeRf6jj4FL-a-GYIgwOvNERjYuqORk9kfwCurowA
CitedBy_id crossref_primary_10_3389_fphar_2023_1143102
crossref_primary_10_1021_acsmeasuresciau_4c00062
crossref_primary_10_3390_cancers15041303
crossref_primary_10_1021_acsabm_3c00984
crossref_primary_10_1166_sam_2023_4438
Cites_doi 10.1200/JCO.18.02178
10.1007/s12010-011-9383-z
10.1016/j.jconrel.2019.04.019
10.1186/s12645-019-0055-y
10.3390/ijms19103264
10.1038/ni1443
10.1016/j.molmed.2014.10.009
10.1038/ni1102-991
10.1186/s13000-018-0743-7
10.1080/21691401.2019.1576702
10.2174/1381612825666190903155321
10.1016/S1470-2045(17)30904-X
10.1056/NEJMoa1809615
10.1088/1361-6528/ab94dc
10.1016/S0378-5173(98)00169-0
10.1039/C9TB00630C
10.1016/j.ijpharm.2005.02.016
10.1038/s41401-020-0426-2
10.1111/jphp.12017
10.1016/S1470-2045(16)30631-3
10.4155/tde-2019-0072
10.1016/j.imlet.2014.07.008
10.4137/CMO.S18006
10.1586/erv.10.174
10.1371/journal.pone.0088557
10.1016/j.msec.2015.08.006
10.1021/acs.nanolett.8b00040
10.1016/j.actbio.2019.03.048
10.7164/antibiotics.41.1915
10.1080/14760584.2020.1858058
10.2217/nnm-2020-0146
10.1016/j.clbc.2020.06.011
10.1016/j.jconrel.2019.04.025
10.1002/adhm.202100008
10.1016/j.biomaterials.2021.120847
10.1186/2051-1426-2-14
10.1001/jamanetworkopen.2020.25109
10.1038/bjc.1974.233
10.1021/acsami.9b13556
10.1021/acsami.0c16357
10.1007/s40259-020-00436-9
10.1371/journal.pone.0185099
10.1016/j.imlet.2005.04.002
10.1002/jcp.29358
10.3390/ma12010031
10.1038/s41568-019-0186-9
10.1038/s41379-018-0153-0
10.1021/acs.accounts.9b00148
10.1016/j.colsurfb.2019.110533
10.1016/j.nano.2020.102240
10.1021/acsami.0c16728
10.2147/OTT.S122974
10.1211/jpp.58.3.0003
10.1126/science.aaa4971
10.1093/annonc/mdu112
10.2217/nnm.14.127
10.3390/molecules26133863
10.1007/s11095-006-9132-0
10.1098/rsfs.2016.0054
10.1002/advs.201802157
10.1016/j.lfs.2021.119110
10.1007/978-3-642-81049-7_8
10.1177/1010428317695023
10.3322/caac.21498
10.1046/j.1365-2567.2003.01738.x
10.1016/j.biomaterials.2019.119649
10.1016/B978-0-12-809717-5.00010-5
10.1039/D0NH00588F
10.1038/s41467-020-14906-9
10.15171/bi.2015.18
10.1111/j.1349-7006.2009.01103.x
10.4110/in.2013.13.5.177
10.1021/jacs.6b09538
10.1001/jamaoncol.2015.0830
10.1097/EDE.0000000000000933
10.1016/j.canlet.2014.09.016
10.2147/IJN.S51880
10.4161/onci.20931
10.1021/acsnano.8b00204
10.1016/j.biomaterials.2021.120988
10.1208/s12249-014-0088-9
10.1038/nature25501
10.2174/138161211796391001
10.18632/oncotarget.3216
10.1016/S1074-7613(94)80017-0
10.1371/journal.pone.0131278
10.1080/17425247.2019.1554647
10.1038/nature21349
10.1001/jamaoncol.2016.1061
10.3390/jcm9020318
10.1016/j.biomaterials.2020.120218
10.1021/acsami.9b11746
10.1016/j.jconrel.2020.02.043
10.1016/j.jconrel.2021.12.013
10.1016/j.actbio.2018.12.028
10.1371/journal.pone.0243550
10.3390/pharmaceutics13122039
10.1002/adtp.201900215
10.1016/j.ijbiomac.2020.01.273
10.1016/j.addr.2021.113905
10.1016/j.jconrel.2015.09.069
10.1016/j.ejps.2019.105136
10.1016/j.colsurfb.2020.111104
10.1016/j.ymthe.2017.10.020
10.1016/S0168-3659(99)00248-5
10.1093/annonc/mdy511.005
10.1016/j.soc.2017.08.005
10.1016/j.jconrel.2019.09.021
10.1016/S1470-2045(19)30026-9
10.1016/j.vascn.2011.07.005
10.1016/j.immuni.2013.07.012
10.1002/adfm.201806087
10.21037/cco.2018.04.01
10.3389/fbioe.2021.680315
10.1038/nature12477
10.1038/nrd2614
10.1021/acsnano.0c05392
10.1016/j.apsusc.2019.144078
10.2217/nnm-2021-0176
10.1021/nn403158n
10.1021/nn5062029
10.2217/nnm-2017-0208
10.1021/acsnano.7b04736
10.1016/j.jconrel.2007.05.037
10.1007/s10549-018-4990-9
10.1016/S0939-6411(00)00087-4
10.1038/359710a0
10.1038/nrc.2016.2
10.1016/0264-410X(94)90265-8
10.3390/biom10070968
10.1186/s12951-019-0541-8
10.1007/s00262-013-1461-3
10.1080/08982100600992302
10.1016/j.addr.2007.04.007
10.1208/s12249-017-0855-5
10.1111/pim.12042
10.3390/ijerph14010068
10.1186/s40425-018-0367-1
10.1016/j.apsb.2019.01.018
10.1001/jamaoncol.2015.3239
10.1021/acsnano.8b00967
10.1016/j.nano.2011.09.010
10.2217/imt-2020-0258
10.1016/j.lfs.2020.118847
10.1016/j.coi.2016.02.008
10.1002/smll.202003543
10.3390/molecules25163620
10.1038/ni.2762
10.3109/10717544.2015.1092183
10.1016/0959-8049(92)90134-N
10.1517/17425247.2010.498473
10.1021/acs.molpharmaceut.6b00932
10.1038/nm.3909
10.1021/acsami.0c16526
10.1016/j.ijpharm.2012.08.042
10.1016/bs.acr.2019.03.006
10.1016/j.cyto.2019.154958
10.1038/nrc3670
10.3109/10717544.2014.920430
10.3390/polym11040630
10.3109/1061186X.2015.1055570
10.2174/1570163811666140616153436
10.1038/aps.2017.44
10.1021/acsami.0c06120
10.1016/j.jddst.2020.101847
10.1021/acs.nanolett.0c01140
10.1002/adma.201806202
10.1016/j.vaccine.2018.03.019
10.1021/acsnano.9b04181
10.1016/S0169-409X(98)00100-8
10.1080/00914037.2020.1869737
10.1172/jci.insight.126908
10.18433/J3XK53
10.1016/j.jddst.2021.102904
10.1039/D1NA00308A
10.1016/j.actbio.2017.11.010
10.1021/acsnano.9b10103
10.1021/acsami.9b01107
10.1016/j.imlet.2017.07.009
ContentType Journal Article
Copyright 2022 Future Medicine Ltd
Copyright_xml – notice: 2022 Future Medicine Ltd
DBID AAYXX
CITATION
NPM
DOI 10.2217/imt-2021-0348
DatabaseName CrossRef
PubMed
DatabaseTitle CrossRef
PubMed
DatabaseTitleList
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1750-7448
EndPage 983
ExternalDocumentID 35852105
10_2217_imt_2021_0348
Genre Journal Article
Review
GrantInformation_xml – fundername: Deanship of Scientific Research at Najran University
  grantid: NU/RC/MRC/11/2
GroupedDBID -
0R
4.4
53G
70G
ACGFS
ACPRK
ADBBV
AENEX
AHMBA
ALMA_UNASSIGNED_HOLDINGS
BENPR
EBS
F5P
HCIFZ
HZ
IAO
IEA
IHR
MV1
NTCAX
O9-
RFM
---
0R~
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
AAWFG
AAYXX
ABUWG
ACWKX
AFFYO
AFKRA
ALIPV
BBNVY
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
EHMNL
EJD
FYUFA
H13
HMCUK
HZ~
ITC
LK8
M1P
M4Z
M7P
OVD
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
RPM
TDBHL
TEORI
TFL
TFMDE
TMEDX
UKHRP
ABJNI
NPM
ID FETCH-LOGICAL-c258t-2f02d25538525b6e20b0c5e068aa2391c223f52abe3282f0fb04553b9550c9be3
ISSN 1750-743X
IngestDate Thu Jan 02 22:36:55 EST 2025
Tue Jul 01 03:05:47 EDT 2025
Thu Apr 24 23:05:03 EDT 2025
Mon Jul 25 10:22:23 EDT 2022
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords breast cancer
nanomedicine
nanoparticles
cancer nanovaccines
vaccines
cancer immunotherapy
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c258t-2f02d25538525b6e20b0c5e068aa2391c223f52abe3282f0fb04553b9550c9be3
ORCID 0000-0002-9812-6562
0000-0002-7025-751X
0000-0003-2979-8776
0000-0002-0604-5360
0000-0002-5545-6422
0000-0002-1421-8962
PMID 35852105
PageCount 27
ParticipantIDs pubmed_primary_35852105
crossref_citationtrail_10_2217_imt_2021_0348
crossref_primary_10_2217_imt_2021_0348
futurescience_futuremedicine_10_2217_imt_2021_0348
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-08-01
PublicationDateYYYYMMDD 2022-08-01
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Immunotherapy
PublicationTitleAlternate Immunotherapy
PublicationYear 2022
Publisher Future Medicine Ltd
Publisher_xml – name: Future Medicine Ltd
References e_1_3_4_3_1
e_1_3_4_175_1
e_1_3_4_110_1
e_1_3_4_152_1
e_1_3_4_133_1
e_1_3_4_179_1
e_1_3_4_114_1
e_1_3_4_156_1
e_1_3_4_61_1
e_1_3_4_84_1
e_1_3_4_137_1
e_1_3_4_118_1
e_1_3_4_42_1
e_1_3_4_80_1
e_1_3_4_7_1
e_1_3_4_46_1
e_1_3_4_69_1
e_1_3_4_65_1
e_1_3_4_88_1
e_1_3_4_182_1
e_1_3_4_121_1
e_1_3_4_140_1
e_1_3_4_163_1
e_1_3_4_125_1
e_1_3_4_144_1
e_1_3_4_167_1
e_1_3_4_186_1
e_1_3_4_72_1
e_1_3_4_95_1
e_1_3_4_106_1
e_1_3_4_129_1
e_1_3_4_148_1
e_1_3_4_53_1
e_1_3_4_91_1
e_1_3_4_30_1
Azvolinsky A (e_1_3_4_35_1) 2020
e_1_3_4_34_1
e_1_3_4_11_1
e_1_3_4_76_1
e_1_3_4_99_1
e_1_3_4_38_1
e_1_3_4_15_1
e_1_3_4_57_1
e_1_3_4_193_1
e_1_3_4_19_1
e_1_3_4_170_1
e_1_3_4_132_1
e_1_3_4_151_1
e_1_3_4_174_1
e_1_3_4_113_1
e_1_3_4_136_1
e_1_3_4_155_1
e_1_3_4_178_1
e_1_3_4_62_1
e_1_3_4_117_1
e_1_3_4_159_1
e_1_3_4_85_1
e_1_3_4_6_1
e_1_3_4_24_1
e_1_3_4_43_1
e_1_3_4_28_1
e_1_3_4_66_1
e_1_3_4_47_1
e_1_3_4_89_1
e_1_3_4_181_1
e_1_3_4_143_1
e_1_3_4_189_1
e_1_3_4_120_1
e_1_3_4_162_1
e_1_3_4_101_1
e_1_3_4_147_1
e_1_3_4_185_1
e_1_3_4_124_1
e_1_3_4_166_1
e_1_3_4_73_1
e_1_3_4_96_1
e_1_3_4_128_1
e_1_3_4_31_1
e_1_3_4_109_1
e_1_3_4_50_1
e_1_3_4_92_1
e_1_3_4_12_1
e_1_3_4_58_1
e_1_3_4_54_1
e_1_3_4_16_1
e_1_3_4_39_1
e_1_3_4_77_1
e_1_3_4_192_1
e_1_3_4_150_1
e_1_3_4_154_1
e_1_3_4_131_1
e_1_3_4_173_1
e_1_3_4_112_1
e_1_3_4_158_1
e_1_3_4_135_1
e_1_3_4_177_1
e_1_3_4_116_1
e_1_3_4_63_1
e_1_3_4_86_1
e_1_3_4_9_1
e_1_3_4_139_1
e_1_3_4_40_1
e_1_3_4_82_1
e_1_3_4_5_1
Chin Y (e_1_3_4_23_1) 1992; 12
e_1_3_4_21_1
e_1_3_4_25_1
e_1_3_4_48_1
e_1_3_4_67_1
e_1_3_4_180_1
e_1_3_4_29_1
e_1_3_4_161_1
e_1_3_4_142_1
e_1_3_4_165_1
e_1_3_4_188_1
e_1_3_4_100_1
e_1_3_4_123_1
e_1_3_4_146_1
e_1_3_4_169_1
e_1_3_4_184_1
Badwaik HR (e_1_3_4_102_1) 2019
Allison AC (e_1_3_4_81_1) 1976
e_1_3_4_104_1
e_1_3_4_97_1
e_1_3_4_108_1
e_1_3_4_51_1
e_1_3_4_70_1
e_1_3_4_93_1
e_1_3_4_13_1
e_1_3_4_59_1
e_1_3_4_55_1
e_1_3_4_32_1
e_1_3_4_17_1
e_1_3_4_78_1
e_1_3_4_36_1
e_1_3_4_191_1
Mina LA (e_1_3_4_20_1) 2019; 11
e_1_3_4_172_1
e_1_3_4_4_1
e_1_3_4_130_1
e_1_3_4_153_1
e_1_3_4_176_1
e_1_3_4_111_1
e_1_3_4_134_1
e_1_3_4_157_1
e_1_3_4_115_1
e_1_3_4_138_1
e_1_3_4_83_1
e_1_3_4_64_1
e_1_3_4_8_1
e_1_3_4_119_1
e_1_3_4_41_1
Fu B (e_1_3_4_74_1) 2018; 39
e_1_3_4_60_1
e_1_3_4_45_1
e_1_3_4_22_1
e_1_3_4_49_1
e_1_3_4_87_1
e_1_3_4_26_1
e_1_3_4_68_1
e_1_3_4_183_1
e_1_3_4_160_1
e_1_3_4_164_1
e_1_3_4_141_1
e_1_3_4_122_1
e_1_3_4_168_1
e_1_3_4_103_1
e_1_3_4_145_1
e_1_3_4_187_1
Basu A (e_1_3_4_44_1) 2019
e_1_3_4_94_1
e_1_3_4_126_1
e_1_3_4_75_1
e_1_3_4_107_1
e_1_3_4_149_1
e_1_3_4_52_1
e_1_3_4_90_1
e_1_3_4_71_1
e_1_3_4_10_1
e_1_3_4_33_1
e_1_3_4_98_1
Brewer JM (e_1_3_4_105_1) 1992; 75
e_1_3_4_14_1
e_1_3_4_37_1
e_1_3_4_56_1
e_1_3_4_79_1
e_1_3_4_18_1
Praveen Kumar G (e_1_3_4_127_1) 2015; 5
e_1_3_4_194_1
e_1_3_4_171_1
Han Y (e_1_3_4_27_1) 2020; 10
e_1_3_4_190_1
References_xml – ident: e_1_3_4_101_1
  doi: 10.1200/JCO.18.02178
– ident: e_1_3_4_69_1
  doi: 10.1007/s12010-011-9383-z
– ident: e_1_3_4_95_1
  doi: 10.1016/j.jconrel.2019.04.019
– ident: e_1_3_4_97_1
  doi: 10.1186/s12645-019-0055-y
– ident: e_1_3_4_150_1
  doi: 10.3390/ijms19103264
– ident: e_1_3_4_26_1
  doi: 10.1038/ni1443
– ident: e_1_3_4_29_1
  doi: 10.1016/j.molmed.2014.10.009
– ident: e_1_3_4_55_1
  doi: 10.1038/ni1102-991
– ident: e_1_3_4_45_1
  doi: 10.1186/s13000-018-0743-7
– ident: e_1_3_4_89_1
  doi: 10.1080/21691401.2019.1576702
– ident: e_1_3_4_116_1
  doi: 10.2174/1381612825666190903155321
– ident: e_1_3_4_48_1
  doi: 10.1016/S1470-2045(17)30904-X
– ident: e_1_3_4_100_1
  doi: 10.1056/NEJMoa1809615
– ident: e_1_3_4_171_1
  doi: 10.1088/1361-6528/ab94dc
– ident: e_1_3_4_104_1
  doi: 10.1016/S0378-5173(98)00169-0
– ident: e_1_3_4_180_1
  doi: 10.1039/C9TB00630C
– volume: 11
  start-page: 321
  year: 2019
  ident: e_1_3_4_20_1
  article-title: Immunotherapy for the treatment of breast cancer: emerging new data
  publication-title: Breast Cancer
– ident: e_1_3_4_109_1
  doi: 10.1016/j.ijpharm.2005.02.016
– ident: e_1_3_4_60_1
  doi: 10.1038/s41401-020-0426-2
– ident: e_1_3_4_62_1
  doi: 10.1111/jphp.12017
– ident: e_1_3_4_52_1
  doi: 10.1016/S1470-2045(16)30631-3
– ident: e_1_3_4_79_1
  doi: 10.4155/tde-2019-0072
– ident: e_1_3_4_91_1
  doi: 10.1016/j.imlet.2014.07.008
– ident: e_1_3_4_8_1
  doi: 10.4137/CMO.S18006
– ident: e_1_3_4_159_1
– ident: e_1_3_4_84_1
  doi: 10.1586/erv.10.174
– ident: e_1_3_4_24_1
  doi: 10.1371/journal.pone.0088557
– ident: e_1_3_4_174_1
  doi: 10.1016/j.msec.2015.08.006
– ident: e_1_3_4_183_1
  doi: 10.1021/acs.nanolett.8b00040
– ident: e_1_3_4_169_1
  doi: 10.1016/j.actbio.2019.03.048
– ident: e_1_3_4_192_1
  doi: 10.7164/antibiotics.41.1915
– ident: e_1_3_4_11_1
  doi: 10.1080/14760584.2020.1858058
– ident: e_1_3_4_161_1
  doi: 10.2217/nnm-2020-0146
– ident: e_1_3_4_19_1
  doi: 10.1016/j.clbc.2020.06.011
– ident: e_1_3_4_80_1
  doi: 10.1016/j.jconrel.2019.04.025
– ident: e_1_3_4_144_1
  doi: 10.1002/adhm.202100008
– ident: e_1_3_4_173_1
  doi: 10.1016/j.biomaterials.2021.120847
– ident: e_1_3_4_15_1
  doi: 10.1186/2051-1426-2-14
– ident: e_1_3_4_37_1
  doi: 10.1001/jamanetworkopen.2020.25109
– ident: e_1_3_4_21_1
  doi: 10.1038/bjc.1974.233
– ident: e_1_3_4_176_1
  doi: 10.1021/acsami.9b13556
– ident: e_1_3_4_138_1
  doi: 10.1021/acsami.0c16357
– ident: e_1_3_4_18_1
  doi: 10.1007/s40259-020-00436-9
– ident: e_1_3_4_92_1
  doi: 10.1371/journal.pone.0185099
– ident: e_1_3_4_107_1
  doi: 10.1016/j.imlet.2005.04.002
– ident: e_1_3_4_164_1
  doi: 10.1002/jcp.29358
– ident: e_1_3_4_179_1
  doi: 10.3390/ma12010031
– ident: e_1_3_4_59_1
  doi: 10.1038/s41568-019-0186-9
– ident: e_1_3_4_3_1
  doi: 10.1038/s41379-018-0153-0
– ident: e_1_3_4_31_1
  doi: 10.1021/acs.accounts.9b00148
– ident: e_1_3_4_119_1
  doi: 10.1016/j.colsurfb.2019.110533
– ident: e_1_3_4_139_1
  doi: 10.1016/j.nano.2020.102240
– ident: e_1_3_4_147_1
  doi: 10.1021/acsami.0c16728
– start-page: 415
  volume-title: Studies in Natural Products Chemistry
  year: 2019
  ident: e_1_3_4_102_1
– ident: e_1_3_4_99_1
  doi: 10.2147/OTT.S122974
– ident: e_1_3_4_110_1
  doi: 10.1211/jpp.58.3.0003
– ident: e_1_3_4_41_1
  doi: 10.1126/science.aaa4971
– ident: e_1_3_4_49_1
  doi: 10.1093/annonc/mdu112
– ident: e_1_3_4_54_1
  doi: 10.2217/nnm.14.127
– ident: e_1_3_4_67_1
  doi: 10.3390/molecules26133863
– ident: e_1_3_4_129_1
  doi: 10.1007/s11095-006-9132-0
– ident: e_1_3_4_189_1
  doi: 10.1098/rsfs.2016.0054
– ident: e_1_3_4_187_1
  doi: 10.1002/advs.201802157
– ident: e_1_3_4_56_1
  doi: 10.1016/j.lfs.2021.119110
– start-page: 58
  volume-title: Lymphocytes, Macrophages, and Cancer
  year: 1976
  ident: e_1_3_4_81_1
  doi: 10.1007/978-3-642-81049-7_8
– ident: e_1_3_4_46_1
  doi: 10.1177/1010428317695023
– ident: e_1_3_4_4_1
  doi: 10.3322/caac.21498
– ident: e_1_3_4_14_1
  doi: 10.1046/j.1365-2567.2003.01738.x
– ident: e_1_3_4_167_1
  doi: 10.1016/j.biomaterials.2019.119649
– ident: e_1_3_4_114_1
  doi: 10.1016/B978-0-12-809717-5.00010-5
– ident: e_1_3_4_157_1
– ident: e_1_3_4_122_1
  doi: 10.1039/D0NH00588F
– ident: e_1_3_4_75_1
  doi: 10.1038/s41467-020-14906-9
– ident: e_1_3_4_160_1
  doi: 10.15171/bi.2015.18
– ident: e_1_3_4_193_1
  doi: 10.1111/j.1349-7006.2009.01103.x
– ident: e_1_3_4_73_1
  doi: 10.4110/in.2013.13.5.177
– ident: e_1_3_4_185_1
  doi: 10.1021/jacs.6b09538
– ident: e_1_3_4_50_1
  doi: 10.1001/jamaoncol.2015.0830
– ident: e_1_3_4_5_1
  doi: 10.1097/EDE.0000000000000933
– ident: e_1_3_4_87_1
  doi: 10.1016/j.canlet.2014.09.016
– ident: e_1_3_4_57_1
  doi: 10.2147/IJN.S51880
– ident: e_1_3_4_93_1
  doi: 10.4161/onci.20931
– ident: e_1_3_4_178_1
  doi: 10.1021/acsnano.8b00204
– ident: e_1_3_4_145_1
  doi: 10.1016/j.biomaterials.2021.120988
– ident: e_1_3_4_124_1
  doi: 10.1208/s12249-014-0088-9
– volume: 5
  start-page: 272
  issue: 5
  year: 2015
  ident: e_1_3_4_127_1
  article-title: Nanoemulsion based targeting in cancer therapeutics
  publication-title: Med. Chem.
– ident: e_1_3_4_36_1
  doi: 10.1038/nature25501
– ident: e_1_3_4_65_1
  doi: 10.2174/138161211796391001
– ident: e_1_3_4_25_1
  doi: 10.18632/oncotarget.3216
– ident: e_1_3_4_94_1
  doi: 10.1016/S1074-7613(94)80017-0
– ident: e_1_3_4_149_1
  doi: 10.1371/journal.pone.0131278
– ident: e_1_3_4_78_1
  doi: 10.1080/17425247.2019.1554647
– ident: e_1_3_4_13_1
  doi: 10.1038/nature21349
– volume: 75
  start-page: 570
  issue: 4
  year: 1992
  ident: e_1_3_4_105_1
  article-title: The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin
  publication-title: Immunology
– ident: e_1_3_4_47_1
  doi: 10.1001/jamaoncol.2016.1061
– ident: e_1_3_4_82_1
  doi: 10.3390/jcm9020318
– ident: e_1_3_4_137_1
  doi: 10.1016/j.biomaterials.2020.120218
– ident: e_1_3_4_172_1
  doi: 10.1021/acsami.9b11746
– ident: e_1_3_4_151_1
  doi: 10.1016/j.jconrel.2020.02.043
– ident: e_1_3_4_188_1
  doi: 10.1016/j.jconrel.2021.12.013
– ident: e_1_3_4_72_1
  doi: 10.1016/j.actbio.2018.12.028
– ident: e_1_3_4_90_1
  doi: 10.1371/journal.pone.0243550
– year: 2020
  ident: e_1_3_4_35_1
  article-title: What is tumor mutational burden?
  publication-title: Cancer Today
– ident: e_1_3_4_7_1
  doi: 10.3390/pharmaceutics13122039
– ident: e_1_3_4_98_1
  doi: 10.1002/adtp.201900215
– ident: e_1_3_4_140_1
  doi: 10.1016/j.ijbiomac.2020.01.273
– ident: e_1_3_4_103_1
  doi: 10.1016/j.addr.2021.113905
– ident: e_1_3_4_76_1
  doi: 10.1016/j.jconrel.2015.09.069
– ident: e_1_3_4_132_1
  doi: 10.1016/j.ejps.2019.105136
– ident: e_1_3_4_162_1
  doi: 10.1016/j.colsurfb.2020.111104
– ident: e_1_3_4_163_1
  doi: 10.1016/j.ymthe.2017.10.020
– ident: e_1_3_4_126_1
  doi: 10.1016/S0168-3659(99)00248-5
– ident: e_1_3_4_39_1
  doi: 10.1093/annonc/mdy511.005
– ident: e_1_3_4_9_1
  doi: 10.1016/j.soc.2017.08.005
– ident: e_1_3_4_131_1
  doi: 10.1016/j.jconrel.2019.09.021
– ident: e_1_3_4_152_1
  doi: 10.1016/S1470-2045(19)30026-9
– ident: e_1_3_4_190_1
  doi: 10.1016/j.vascn.2011.07.005
– ident: e_1_3_4_30_1
  doi: 10.1016/j.immuni.2013.07.012
– ident: e_1_3_4_71_1
  doi: 10.1002/adfm.201806087
– ident: e_1_3_4_16_1
  doi: 10.21037/cco.2018.04.01
– ident: e_1_3_4_34_1
  doi: 10.3389/fbioe.2021.680315
– ident: e_1_3_4_42_1
  doi: 10.1038/nature12477
– ident: e_1_3_4_155_1
  doi: 10.1038/nrd2614
– ident: e_1_3_4_175_1
  doi: 10.1021/acsnano.0c05392
– ident: e_1_3_4_112_1
  doi: 10.1016/j.apsusc.2019.144078
– volume: 12
  start-page: 1463
  issue: 5
  year: 1992
  ident: e_1_3_4_23_1
  article-title: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer
  publication-title: Anticancer Res.
– ident: e_1_3_4_43_1
– ident: e_1_3_4_58_1
  doi: 10.2217/nnm-2021-0176
– ident: e_1_3_4_186_1
  doi: 10.1021/nn403158n
– ident: e_1_3_4_17_1
  doi: 10.1021/nn5062029
– ident: e_1_3_4_77_1
  doi: 10.2217/nnm-2017-0208
– ident: e_1_3_4_184_1
  doi: 10.1021/acsnano.7b04736
– ident: e_1_3_4_136_1
  doi: 10.1016/j.jconrel.2007.05.037
– ident: e_1_3_4_6_1
  doi: 10.1007/s10549-018-4990-9
– ident: e_1_3_4_113_1
  doi: 10.1016/S0939-6411(00)00087-4
– ident: e_1_3_4_146_1
  doi: 10.1038/359710a0
– ident: e_1_3_4_156_1
  doi: 10.1038/nrc.2016.2
– ident: e_1_3_4_106_1
  doi: 10.1016/0264-410X(94)90265-8
– ident: e_1_3_4_66_1
  doi: 10.3390/biom10070968
– ident: e_1_3_4_165_1
  doi: 10.1186/s12951-019-0541-8
– volume: 39
  start-page: 893
  issue: 3
  year: 2018
  ident: e_1_3_4_74_1
  article-title: Application of multifunctional nanomaterials in cancer vaccines (Review)
  publication-title: Oncol. Rep.
– ident: e_1_3_4_83_1
  doi: 10.1007/s00262-013-1461-3
– ident: e_1_3_4_108_1
  doi: 10.1080/08982100600992302
– ident: e_1_3_4_117_1
  doi: 10.1016/j.addr.2007.04.007
– ident: e_1_3_4_111_1
  doi: 10.1208/s12249-017-0855-5
– ident: e_1_3_4_121_1
  doi: 10.1111/pim.12042
– ident: e_1_3_4_28_1
  doi: 10.3390/ijerph14010068
– ident: e_1_3_4_40_1
  doi: 10.1186/s40425-018-0367-1
– ident: e_1_3_4_166_1
  doi: 10.1016/j.apsb.2019.01.018
– ident: e_1_3_4_51_1
  doi: 10.1001/jamaoncol.2015.3239
– ident: e_1_3_4_96_1
  doi: 10.1021/acsnano.8b00967
– ident: e_1_3_4_88_1
  doi: 10.1016/j.nano.2011.09.010
– ident: e_1_3_4_10_1
  doi: 10.2217/imt-2020-0258
– ident: e_1_3_4_142_1
  doi: 10.1016/j.lfs.2020.118847
– ident: e_1_3_4_191_1
  doi: 10.1016/j.coi.2016.02.008
– ident: e_1_3_4_143_1
  doi: 10.1002/smll.202003543
– ident: e_1_3_4_135_1
  doi: 10.3390/molecules25163620
– ident: e_1_3_4_32_1
  doi: 10.1038/ni.2762
– ident: e_1_3_4_115_1
  doi: 10.3109/10717544.2015.1092183
– ident: e_1_3_4_22_1
  doi: 10.1016/0959-8049(92)90134-N
– ident: e_1_3_4_70_1
  doi: 10.1517/17425247.2010.498473
– ident: e_1_3_4_123_1
  doi: 10.1021/acs.molpharmaceut.6b00932
– ident: e_1_3_4_53_1
  doi: 10.1038/nm.3909
– ident: e_1_3_4_154_1
  doi: 10.1021/acsami.0c16526
– ident: e_1_3_4_194_1
  doi: 10.1016/j.ijpharm.2012.08.042
– ident: e_1_3_4_33_1
  doi: 10.1016/bs.acr.2019.03.006
– ident: e_1_3_4_141_1
  doi: 10.1016/j.cyto.2019.154958
– ident: e_1_3_4_12_1
  doi: 10.1038/nrc3670
– ident: e_1_3_4_125_1
  doi: 10.3109/10717544.2014.920430
– ident: e_1_3_4_134_1
  doi: 10.3390/polym11040630
– ident: e_1_3_4_158_1
– ident: e_1_3_4_63_1
  doi: 10.3109/1061186X.2015.1055570
– ident: e_1_3_4_61_1
  doi: 10.2174/1570163811666140616153436
– ident: e_1_3_4_170_1
  doi: 10.1038/aps.2017.44
– ident: e_1_3_4_177_1
  doi: 10.1021/acsami.0c06120
– start-page: 295
  volume-title: Advances in Cancer Research
  year: 2019
  ident: e_1_3_4_44_1
– ident: e_1_3_4_68_1
  doi: 10.1016/j.jddst.2020.101847
– ident: e_1_3_4_133_1
  doi: 10.1021/acs.nanolett.0c01140
– ident: e_1_3_4_153_1
  doi: 10.1002/adma.201806202
– ident: e_1_3_4_118_1
  doi: 10.1016/j.vaccine.2018.03.019
– ident: e_1_3_4_182_1
  doi: 10.1021/acsnano.9b04181
– ident: e_1_3_4_130_1
  doi: 10.1016/S0169-409X(98)00100-8
– ident: e_1_3_4_64_1
  doi: 10.1080/00914037.2020.1869737
– ident: e_1_3_4_38_1
  doi: 10.1172/jci.insight.126908
– ident: e_1_3_4_120_1
  doi: 10.18433/J3XK53
– ident: e_1_3_4_86_1
  doi: 10.1016/j.jddst.2021.102904
– ident: e_1_3_4_148_1
  doi: 10.1039/D1NA00308A
– ident: e_1_3_4_168_1
  doi: 10.1016/j.actbio.2017.11.010
– ident: e_1_3_4_128_1
  doi: 10.1021/acsnano.9b10103
– ident: e_1_3_4_181_1
  doi: 10.1021/acsami.9b01107
– volume: 10
  start-page: 727
  issue: 3
  year: 2020
  ident: e_1_3_4_27_1
  article-title: PD-1/PD-L1 pathway: current researches in cancer
  publication-title: Am. J. Cancer Res.
– ident: e_1_3_4_85_1
  doi: 10.1016/j.imlet.2017.07.009
SSID ssj0064764
ssib008506956
Score 2.2758174
SecondaryResourceType review_article
Snippet Breast cancer is one of the most common causes of cancer-related morbidity and mortality in women worldwide. Early diagnosis and an appropriate therapeutic...
SourceID pubmed
crossref
futurescience
SourceType Index Database
Enrichment Source
Publisher
StartPage 957
SubjectTerms breast cancer
cancer immunotherapy
cancer nanovaccines
nanomedicine
nanoparticles
vaccines
Title Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges
URI http://dx.doi.org/10.2217/imt-2021-0348
https://www.ncbi.nlm.nih.gov/pubmed/35852105
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1750-7448
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0064764
  issn: 1750-743X
  databaseCode: RPM
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NT9swFLcKu0yaprEv2AbyYeqlzZY6H4136yoQm1TWQ5G6XSLbOGolmiJID_BX8CfvPTtxkgoktkuUOH5uk_eL_Z793s-EfPbFUGsWCS9mWeLh0pknFEYRKsYHQqssMElhk7P49Dz8OY_mnc59I2ppU8gv6u7BvJL_0SqUgV4xS_YfNOsahQI4B_3CETQMxyfpGGeUzCZDI7uSb2Jbob9cVyvmJojwO8adF70x1rju_cCEkDLtyrA9_bpCE3yTG2pVs5YwrjZYuWmari1Bh5PFymJksl6IFZz3_oBJ6u5ijqZNZR9dLutZVizHlLlaEMze32KxdGPESF6AbyzMnE8ZaFBOTYBXWwXGVb0pmCMemChzO9g0yyy9puuCwybUWKND5Za-uhybud30ZrvbZ8xwRS1XBcCDYYhY2XyLXntr2HPBiOAGYQMpiKconqL4DnnGhnHMtuZ_kN-PI_uQHevjcGgIytyDWhZXbO5r69-0rJ4Xli6mNHG2_Blj18xekZelQ0JHFl17pKPz16Q7tYzmt306qxP0bvq0S6c11_ntG5JWEKQVBOkyp00IUoAgtRCkFoK0haRvtAVACgCkNQDfkvOT49n41Cv37PAUixJ44sxnF-CmBknEIhlr5ktfRdqPEyEYfPcKzNEsYkLqAJz9zM8k-BRRIDl4yopD6Tuym69zvU-oiKBiqJJhBmZuMhjIkKuMc-YLyYM41gekX73TVJWE9rivymX6oEYPSNdVv7JMLo9VZC0Fpfaqem2PCb23WnRtB-CIM_BePjz1dz-S5_VH9InsFtcbfQgWbyGPyM7ZdHJkoPgXm02r-g
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emerging+Advances+in+Nanomedicine+for+Breast+Cancer+Immunotherapy%3A+Opportunities+and+Challenges&rft.jtitle=Immunotherapy&rft.au=Ahmad%2C+Mohammad+Zaki&rft.au=Alasiri%2C+Ali+S&rft.au=Alasmary%2C+Mohammed+Yahia&rft.au=Abdullah%2C+MM&rft.date=2022-08-01&rft.issn=1750-743X&rft.eissn=1750-7448&rft.volume=14&rft.issue=12&rft.spage=957&rft.epage=983&rft_id=info:doi/10.2217%2Fimt-2021-0348&rft.externalDBID=n%2Fa&rft.externalDocID=10_2217_imt_2021_0348
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-743X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-743X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-743X&client=summon